[
    [
        {
            "time": "",
            "original_text": "泰格医药(300347)：营收及扣非净利润增速逐季加快 主业逐步恢复",
            "features": {
                "keywords": [
                    "泰格医药",
                    "营收",
                    "扣非净利润",
                    "增速",
                    "主业恢复"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(300347)：营收及扣非净利润增速逐季加快 主业逐步恢复",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【国元医药|点评】泰格医药三季报点评：Q3业务进一步恢复，看好行业长期发展",
            "features": {
                "keywords": [
                    "泰格医药",
                    "三季报",
                    "Q3业务恢复",
                    "行业长期发展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国元医药|点评】泰格医药三季报点评：Q3业务进一步恢复，看好行业长期发展",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药(03347-HK)首9月盈利13.18亿增1.5倍",
            "features": {
                "keywords": [
                    "泰格医药",
                    "首9月",
                    "盈利",
                    "增长1.5倍"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(03347-HK)首9月盈利13.18亿增1.5倍",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]